Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0E6EP
|
|||
| Drug Name |
PMID25656651-Compound-19b
|
|||
| Drug Type |
Small molecular drug
|
|||
| Company |
4SC AG [DE]
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C23H19N5O3S2
|
|||
| Canonical SMILES |
CC1=C(C=C(C=C1)NC(=O)C2=CC=C(S2)C=CC(=O)NO)NC3=NC(=CS3)C4=CN=CC=C4
|
|||
| InChI |
1S/C23H19N5O3S2/c1-14-4-5-16(25-22(30)20-8-6-17(33-20)7-9-21(29)28-31)11-18(14)26-23-27-19(13-32-23)15-3-2-10-24-12-15/h2-13,31H,1H3,(H,25,30)(H,26,27)(H,28,29)/b9-7+
|
|||
| InChIKey |
DFZFLIGZEDFNOL-VQHVLOKHSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Fusion protein Bcr-Abl (Bcr-Abl) | Target Info | Inhibitor | [1] |
| Fusion protein Bcr-Abl T315I mutant (Bcr-Abl T315I) | Target Info | Inhibitor | [1] | |
| Target's Patent Info | Fusion protein Bcr-Abl (Bcr-Abl) | Target's Patent Info | [1] | |
| Fusion protein Bcr-Abl T315I mutant (Bcr-Abl T315I) | Target's Patent Info | [1] | ||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.